Abstract
T cell targeting immunotherapy is now considered a possible strategy in acute myelogenous leukaemia (AML), and IFNγ release may then contribute to the antileukaemic effects. We investigated the effects of IFNγ on native human AML cells. Normal T cells could be activated to release IFNγ in the presence of AML cells. Furthermore, high levels of CD119 (IFNγ receptor α chain) expression were observed for all 39 patients examined. Receptor expression was decreased after exposure to exogenous IFNγ, and receptor ligation caused Stat1 phosphorylation but no phosphorylation of the alternative messengers Erk1/2. The effect of exogenous IFNγ on AML blast proliferation was dependent on the local cytokine network and IFNγ (1) inhibited proliferation in the presence of exogenous IL1β, GM-CSF, G-CSF and SCF; (2) had divergent effects in the presence of IL3 and Flt3 (65 patients examined); (3) inhibited proliferation in the presence of endothelial cells but had divergent effects in the presence of fibroblasts, osteoblasts and normal stromal cells (65 patients examined). IFNγ increased stress-induced (spontaneous) in vitro apoptosis as well as cytarabine-induced apoptosis only for a subset of patients. Furthermore, IFNγ decreased the release of proangiogenic CXCL8 and increased the release of antiangiogenic CXCL9–11. We conclude that IFNγ can be released in the presence of native human AML cells and affect AML cell proliferation, regulation of apoptosis and the balance between pro- and antiangiogenic chemokine release.
Similar content being viewed by others
Abbreviations
- AML:
-
Acute myeloid leukaemia
References
Billiau A (1996) Interferon-gamma: biology and role in pathogenesis. Adv Immunol 62:61–130
Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563–591
Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W (2004) Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50:197–222
Bruserud O (1999) Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia 13:1175–1187
Bruserud O, Tjonnfjord G, Gjertsen BT, Foss B, Ernst P (2000) New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients. Stem Cells 18:343–351
Bruserud O, Hamann W, Patel S, Ehninger G, Schmidt H, Pawelec G (1993) IFN-gamma and TNF-alpha secretion by CD4+ and CD8+ TCR alpha beta + T-cell clones derived early after allogeneic bone marrow transplantation. Eur J Haematol 51:73–79
Bruserud O (1998) Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells. Cancer Immunol Immunother 46:221–228
Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW (1993) Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol 16:159–163
Beran M, Andersson B, Kantarjian H, Keating M, Rios A, McCredie KB, Freireich EJ, Gutterman J (1987) Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia 1:52–57
Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23:96–101
Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, Nolan GP (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118:217–228
Mizuno S, Emi N, Kasai M, Ishitani A, Saito H (2000) Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia. Br J Haematol 111:280–282
Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D (1998) Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol 28:90–103
Munker R, Andreeff M (1996) Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther 2:147–159
Nara N (1993) Combined effect of interferon-gamma and tumor necrosis factor-alpha causing suppression of leukemic blast progenitors in acute myeloblastic leukemia. Leuk Lymphoma 10:201–207
Murohashi I, Hoang T (1991) Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 78:1085–1095
Kerangueven F, Sempere C, Tabilio A, Mannoni P (1990) Effects of transforming growth factor beta, tumor necrosis factor alpha, interferon gamma and LIF-HILDA on the proliferation of acute myeloid leukemia cells. Eur Cytokine Netw 1:99–107
Howell AL, Stukel TA, Bloomfield CD, Davey FR, Ball ED (1990) Induction of differentiation in blast cells and leukemia colony-forming cells from patients with acute myeloid leukemia. Blood 75:721–729
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783–1786
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69–79
Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT (2003) Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88:416–428
Bruserud O, Gjertsen BT, Foss B, Huang TS (2001) New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells—the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 19:1–11
Glenjen N, Ersvaer E, Ryningen A, Bruserud O (2004) In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts. Int J Cancer 111:858–867
Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O (2005) In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic interleukin 8. Leuk Res 29:185–196
Bruserud O, Tronstad KJ, Berge R (2005) In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. J Cancer Res Clin Oncol 131:377–384
Rochet N, Dubousset J, Mazeau C, Zanghellini E, Farges MF, de Novion HS, Chompret A, Delpech B, Cattan N, Frenay M et al (1999) Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int J Cancer 82:282–285
Rochet N, Leroy P, Far DF, Ollier L, Loubat A, Rossi B (2003) CAL72: a human osteosarcoma cell line with unique effects on hematopoietic cells. Eur J Haematol 70:43–52
Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT (2004) Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89:391–402
Bruserud O, Glenjen N, Ryningen A, Ulvestad E (2003) In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines. Leuk Res 27:455–464
Wendelbo O, Bruserud O (2003) Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay. J Hematother Stem Cell Res 12:525–535
Bruserud O, Mentzoni L, Foss B, Bergheim J, Berentsen S, Nesthus I (1996) Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-gamma secretion. Cancer Immunol Immunother 43:275–282
Costello RT, Mallet F, Chambost H, Sainty D, Gastaut JA, Olive D (1999) Differential modulation of immune recognition molecules by interleukin-7 in human acute leukaemias. Eur Cytokine Netw 10:87–96
Lecchi M, Lovisone E, Genetta C, Peruccio D, Resegotti L, Richiardi P (1989) Gamma-IFN induces a differential expression of HLA-DR, DQ and DP antigens on peripheral blood myeloid leukemic blasts at various stages of differentiation. Leuk Res 13:221–226
Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O (2005) Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 5:229–248
Stolze B, Emmendorffer A, Corbacioglu S, Konig A, Welte K, Ebell W (1995) Effects of bone marrow fibroblasts on the proliferation and differentiation of myeloid leukemic cell lines. Exp Hematol 23:1378–1387
Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ (1994) Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 22:1252–1260
Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29:448–457
Bruserud O, Ulvestad E (2003) Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells. Cancer Immunol Immunother 52:215–225
Bruserud O, Wendelboe O (2001) Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opin Biol Ther 1:1005–1016
Selleri C, Maciejewski JP, Sato T, Young NS (1996) Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87:4149–4157
Kawano Y, Takaue Y, Hirao A, Abe T, Saito S, Matsunaga K, Watanabe T, Hirose M, Ninomiya T, Kuroda Y et al (1991) Synergistic effect of recombinant interferon-gamma and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood 77:2118–2121
Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L (1993) Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579–2584
Shiohara M, Koike K, Nakahata T (1993) Synergism of interferon-gamma and stem cell factor on the development of murine hematopoietic progenitors in serum-free culture. Blood 81:1435–1441
Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T (1996) Interferon-gamma induces ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 229:21–26
Romagnani S, Giudizi MG, Biagiotti R, Almerigogna F, Mingari C, Maggi E, Liang CM, Moretta L (1986) B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes. J Immunol 136:3513–3516
Grawunder U, Melchers F, Rolink A (1993) Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur J Immunol 23:544–551
Novelli F, D’Elios MM, Bernabei P, Ozmen L, Rigamonti L, Almerigogna F, Forni G, Del Prete G (1997) Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol 159:206–213
Novelli F, Giovarelli M, Reber-Liske R, Virgallita G, Garotta G, Forni G (1991) Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation. J Immunol 147:1445–1452
Liu Y, Janeway CA Jr (1990) Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 172:1735–1739
Acknowledgement
The work was supported by the Norwegian Cancer Society and Helse-Vest. The technical assistance of Laila Mentzoni and Kristin Paulsen is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ersvaer, E., Skavland, J., Ulvestad, E. et al. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunol Immunother 56, 13–24 (2007). https://doi.org/10.1007/s00262-006-0159-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-006-0159-1